Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965481 | 1.00 | ATM (0.45) | ATMALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL19097297 | 0.92 | ATM (0.52) | ATMALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL21360450 | 0.86 | ATM (0.43) | ATMALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL3941124 | 0.86 | ATM (0.43) | ATMALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL5137199 | 0.84 | SMN1; SMN2 (0.40) | ATMALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL19390116 | 0.83 | ATM (0.41) | ATMALDH1A1KMT2AMEN1PARP1 | |
| SCHEMBL29065904 | 0.82 | ATM (0.40) | ATMALDH1A1PARP1DDB1CRBN | |
| SCHEMBL3635011 | 0.81 | OPRK1 (0.33) | ELANE | |
| SCHEMBL10174353 | 0.81 | ELANE (0.39) | KMT2AMEN1ELANE | |
| SCHEMBL9965482 | 0.81 | ELANE (0.39) | KMT2AMEN1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960347-B1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 (17BETA-HSD3) INHIBITORS | STERIX LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-8119627-B2 | Heterocyclic compounds as inhibitors of 17beta-HSD3 | STERIX LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023710-A1 | Compound | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2007003934-A2 | 17BETA-HYDR0XYSTER0ID DEHYDROGENASE TYPE 3 (17BETA-HSD3 ) INHIBITORS | STERIX LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023710-A1 | Compound | NR1H3, NR1H2, NR1H4 | ATM 2968/4885ALDH1A1 2109/4885KMT2A 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.